Abbonarsi

The role of eosinophils in chronic spontaneous urticaria - 08/06/20

Doi : 10.1016/j.jaci.2020.03.005 
Sabine Altrichter, MD a, , Stefan Frischbutter, PhD a, , Jie Shen Fok, MD a, b, c, , Pavel Kolkhir, MD a, d, , Qingqing Jiao, PhD a, e, , Per Stahl Skov, MD f, g, h, Martin Metz, MD a, Martin K. Church, PhD, DSc a, Marcus Maurer, MD a,
a Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany 
b Department of Respiratory Medicine, Box Hill Hospital, Melbourne, Australia 
c Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia 
d I.M. Sechenov First Moscow State Medical University (Sechenov University), Division of Immune-Mediated Skin Diseases, Moscow, Russia 
e Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, China 
f Dermatological Department, University Hospital of Southern Denmark, Odense, Denmark 
g RefLab ApS, Copenhagen, Denmark 
h Institute of Immunology, National University of Copenhagen, Copenhagen, Denmark 

Corresponding author: Marcus Maurer, MD, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany.Allergie-Centrum-CharitéDepartment of Dermatology and AllergyCharité-Universitätsmedizin BerlinCharitéplatz 1BerlinD-10117Germany

Abstract

Chronic spontaneous urticaria (CSU) is considered to be primarily a mast cell–driven disease. However, recent evidence suggests that eosinophils may also have an axial role in symptomology. Histologic studies have demonstrated the presence of both eosinophils and eosinophil granules, indicative of activation, in CSU lesions. Although many allergic and inflammatory conditions are associated with a peripheral blood eosinophilia, the converse appears to be the case in CSU, with a peripheral blood eosinopenia being observed in many patients. Possible mechanisms include the depletion of blood eosinophils by recruitment into the skin during active disease and immunologic destruction in the blood. We also address in some detail the interactions between eosinophils and mast cells, particularly the cytokine cross-talk of these cells and mediator release possibly leading to clinical symptoms. Also, activation by eosinophil proteins of the coagulation pathway leads to the generation of thrombin and increased mast cell degranulation. Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti–IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. Clearly, a new picture of an important role of eosinophils in the pathogenesis of CSU is emerging.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Urticaria chronic spontaneous urticaria, mast cell, eosinophil

Abbreviations used : CCL11, CCL24, CLC, CSU, ECP, EDN, EPO, MBP, MCP3, PAF, PAR, Siglec, VEGF


Mappa


 P. Kolkhir was supported by a GA2LEN fellowship. This project benefitted from the support of the GA2LEN network of Urticaria Centers of Reference and Excellence (www.ga2len-ucare.com) and the Russian Academic Excellence Project 5-100.
 Disclosure of potential conflict of interest: S. Altrichter is or was recently a speaker and/or advisor for and/or has received research funding from Allakos, AstraZeneca, Moxie, and Sanofi. P. Kolkhir is or was recently a speaker for Novartis and Roche. M. Maurer is or was recently a speaker and/or advisor for and/or has received research funding from Allakos, Aralez, AstraZeneca, FAES, Genentech, Menarini, Novartis, Leo Pharma, Lilly, Moxie, MSD, Roche, Sanofi, UCB, and Uriach. M. Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, Moxie, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach. The rest of the authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 145 - N° 6

P. 1510-1516 - Giugno 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Epithelial barriers in allergy and asthma
  • Peter W. Hellings, Brecht Steelant
| Articolo seguente Articolo seguente
  • Environmental factors in epithelial barrier dysfunction
  • Zeynep Celebi Sözener, Lacin Cevhertas, Kari Nadeau, Mübeccel Akdis, Cezmi A. Akdis

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.